gefitinib has been researched along with Stevens-Johnson Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, LK; Dinglin, XX; Hou, X; Huang, JJ; Ma, SX; Qin, T; Wang, Z; Zeng, YD | 1 |
| Treudler, R; Zouboulis, CC | 1 |
2 other study(ies) available for gefitinib and Stevens-Johnson Syndrome
| Article | Year |
|---|---|
Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Stevens-Johnson Syndrome | 2015 |
Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Cells, Cultured; Drug Eruptions; ErbB Receptors; Facial Dermatoses; Fatal Outcome; Gefitinib; Humans; Male; Protein-Tyrosine Kinases; Quinazolines; Skin; Stevens-Johnson Syndrome | 2005 |